What does CJC-1295 do? What published studies found

What does research show CJC-1295 does in the body?

CJC-1295 is a lab-made copy of growth hormone-releasing hormone (GHRH), the signal that tells the pituitary gland to release growth hormone. In rats, with no animal count in the abstract, CJC-1295 produced a fourfold larger growth hormone response over two hours than the natural fragment hGRF(1-29), and albumin-bound versions of the peptide were active in cultured rat pituitary cells, which are animal and cell results and not human ones (Jetté et al., Endocrinology, 2005). In two placebo-controlled trials of healthy adults aged 21 to 61, with no participant count in the abstract, the downstream result was higher growth hormone and IGF-I in the blood, a hormone-level finding with no clinical outcome measured (Teichman et al., 2006). CJC-1295 acts on the signal, upstream of the hormone itself.

Growth hormone arrives in pulses, not a steady stream. In healthy men aged 20 to 40, with no participant count in the abstract, sampled every 20 minutes overnight one week after one exposure, the pulses kept their usual frequency and size while the low points between pulses rose 7.5-fold, mean growth hormone rose 46% and IGF-I rose 45%, a hormone-level result from one study with no clinical outcome (Ionescu and Frohman, Journal of Clinical Endocrinology & Metabolism, 2006).

That is a lab description of a hormone rhythm in healthy men. It is not a claim about what any person would notice.

Evidence limits

Does research show that CJC-1295 works?

Whether something works depends on the question asked. A raised hormone level is a lab finding. An outcome, such as strength or body weight, needs its own trial. Teichman's main outcome measures were peak levels and total exposure of growth hormone and IGF-I, plus the peptide's own pharmacokinetics, meaning how it moves through and leaves the body (Teichman et al., 2006). Nothing in those measures tests strength or body shape.

The same logic covers the pair of CJC-1295 and ipamorelin. Dominikowski et al. (2026) describe controlled clinical evidence for synergy or meaningful body-composition outcomes from CJC-1295 with ipamorelin in healthy people as limited; this is a narrative review's assessment.

What did the human studies of CJC-1295 find?

Three published human papers report CJC-1295 data, and all three list L. A. Frohman as an author. Teichman et al. ran two randomised, placebo-controlled trials of 28 and 49 days in healthy adults aged 21 to 61 and found raised growth hormone and IGF-I and a half-life of 5.8 to 8.1 days, though the abstract gives no participant count and measures hormone levels, not clinical outcomes (Journal of Clinical Endocrinology & Metabolism, 2006). Ionescu and Frohman sampled healthy men aged 20 to 40 overnight and found preserved pulses in a hormone-level study with no participant count in the abstract and no clinical outcome (2006). Sackmann-Sala et al. analysed serum from 11 healthy men and found five changed protein spots, which the authors proposed as possible biomarkers and not as health outcomes (Growth Hormone & IGF Research, 2009).

The protein study asked a narrow question: could blood proteins mark growth hormone activity? One week after one exposure in 11 healthy men, two protein spots fell (an apolipoprotein A1 isoform and a transthyretin isoform) and three rose (beta-hemoglobin and two albumin-linked fragments), and the authors proposed them as possible biomarkers, not as health outcomes, from one small study (Sackmann-Sala et al., 2009).

The three human papers reviewed here concern healthy volunteers and hormone or blood-test measurements, and do not establish clinical outcomes (Teichman et al., 2006; Ionescu and Frohman, 2006; Sackmann-Sala et al., 2009). The Teichman and Ionescu abstracts give no participant count. A study can be careful and still be too short or too narrow to answer questions the reader brings to it.

How long did it take for studies to show changes with CJC-1295?

In two placebo-controlled trials of healthy adults aged 21 to 61, with no participant count in the abstract, mean growth hormone stayed raised for six days or more and mean IGF-I for 9 to 11 days after one exposure, and after repeated exposures mean IGF-I stayed above baseline for up to 28 days, all as blood-test results with no clinical outcome (Teichman et al., Journal of Clinical Endocrinology & Metabolism, 2006). In an overnight sampling study of healthy men aged 20 to 40, with no participant count in the abstract, one week after one exposure trough growth hormone was 7.5-fold higher and IGF-I was 45% higher, again a hormone-level result from a single study (Ionescu and Frohman, 2006).

No study found recorded when, or whether, participants noticed anything. So the studies cannot say how long it takes to see or feel a result, and a timeline for hormone levels is not a timeline for the body changes that people search for. The studies found do not support turning a blood-test curve into a promise.

Have studies found that CJC-1295 builds muscle?

No published human trial found has measured muscle mass or strength after CJC-1295. The human papers report hormone levels, pharmacokinetics and serum proteins in healthy adults and men, two of them with no participant count in the abstract (Teichman et al., 2006; Ionescu and Frohman, 2006; Sackmann-Sala et al., 2009). The nearest body-composition data come from mice bred without GHRH, in which relative lean mass was normal in every treated group, a result in a growth-deficient mouse model that does not describe healthy muscle or any human (Alba et al., American Journal of Physiology-Endocrinology and Metabolism, 2006). A 2026 narrative review finds no peer-reviewed support for body-composition or performance effects, a secondary summary and not trial data (Dominikowski et al., 2026).

Those mice lack the GHRH gene, so the study asked whether CJC-1295 can stand in for a missing signal in a growing animal. It did not test muscle growth in a healthy adult (Alba et al., 2006).

In a 26-week trial of 412 adults with HIV and extra abdominal fat, tesamorelin, a different GHRH analogue, was followed by a 15.2% fall in visceral fat measured by CT scan against a 5.0% rise on placebo; the result belongs to an approved medicine for one stated condition, measured fat and not muscle, and cannot be carried across to CJC-1295 (Falutz et al., New England Journal of Medicine, 2007).

Have studies reported weight gain or weight loss with CJC-1295?

No published CJC-1295 trial found reports body weight as a result in people. The one trial registered to study body fat, in HIV-infected adults with visceral obesity, is terminated and has no posted results (ClinicalTrials.gov NCT00267527, checked 14 October 2026). A 2026 narrative review rates the direct effect of GHRH analogues on appetite and body composition as limited, and links appetite increase mainly to older ghrelin-mimetic peptides such as GHRP-2 and GHRP-6, with ipamorelin less so, as a class-level reading and not a CJC-1295 trial result (Dominikowski et al., Frontiers in Endocrinology, 2026). The records found report neither weight gain nor weight loss from CJC-1295.

The US label for tesamorelin, an approved GHRH analogue for HIV-infected adults with lipodystrophy, states that the medicine is not indicated for weight loss management because it has a weight-neutral effect. It also lists fluid retention, thought to relate to growth hormone secretion, with oedema and joint pain among its adverse reactions; these are label statements about tesamorelin, not CJC-1295 (Egrifta SV label, DailyMed, effective 29 July 2026). Fluid is not fat, and no study found measured it for CJC-1295.

Have studies reported hair loss with CJC-1295?

No published study found reports hair loss as an outcome of CJC-1295. A Europe PMC search on 14 October 2026 for CJC-1295 with hair or alopecia returned 10 records. By title, none reports a CJC-1295 trial. The titles cover reviews, doping-analysis papers, a user survey, a case report and conference abstracts. The human trials report hormone measurements and no serious adverse reactions in healthy adults aged 21 to 61, with no participant count or event counts in the abstract (Teichman et al., Journal of Clinical Endocrinology & Metabolism, 2006). Not studied is different from shown not to happen. The evidence found cannot answer this question in either direction.

Online reports on this question are anecdotes. An anecdote cannot separate a peptide from age, genetics, other products or chance. That is why trials use placebo groups. For harms that the studies did record, see the CJC-1295 side effects page.

What does research show CJC-1295 with ipamorelin does in the body?

Ipamorelin is a different kind of molecule. It releases growth hormone through the GHRP receptor, a ghrelin-type receptor, while CJC-1295 acts on the GHRH receptor. In conscious pigs, ACTH and cortisol levels after ipamorelin were not significantly different from those after GHRH stimulation, an animal finding that does not establish selectivity in humans (Raun et al., European Journal of Endocrinology, 1998). In eight healthy men at each of five levels, ipamorelin alone produced a single episode of growth hormone release peaking at 0.67 hours, with a terminal half-life of 2 hours, in a study with no CJC-1295 in it (Gobburu et al., Pharmaceutical Research, 1999). No controlled human trial of the pair was found, and a 2026 narrative review calls controlled evidence limited (Dominikowski et al., 2026).

The idea that the two peptides amplify each other is common online. A 2026 review traces it to an anecdotal rationale and says controlled evidence for synergy, or for body-composition change in healthy people, remains limited (Dominikowski et al., 2026). Ipamorelin's published phase 2 trial, a small proof-of-concept study of 117 enrolled patients with a broad range of conditions recovering from bowel surgery, found no significant difference from placebo on its main efficacy measure (Beck et al., International Journal of Colorectal Disease, 2014). That trial studied a hospital problem, not growth hormone effects in healthy people.

What does research show CJC-1295 without DAC does?

No published human study of CJC-1295 without DAC was found in the sources checked, so this page can report no measured human result for it. A 2026 narrative review puts it in the lowest of four evidence tiers, with claims resting on preclinical extrapolation and user narratives (Dominikowski et al., Frontiers in Endocrinology, 2026). The related unmodified fragment, sermorelin (GHRH 1-29), once held US approval for children with growth hormone deficiency, and the review says effects described for without-DAC material are mostly borrowed from it (Dominikowski et al., 2026). Borrowed evidence is not measured evidence.

The review says sermorelin's US approvals were withdrawn effective 18 June 2009 and that the FDA later determined the product was not withdrawn for safety or effectiveness reasons (Dominikowski et al., 2026). That is history for a different molecule. The DAC and no DAC comparison guide shows how the two CJC-1295 forms differ in structure and in the published record.

Which clinical trials of CJC-1295 have been published or registered?

Five published primary studies and one registry record make up the CJC-1295 record found for this page, and three of the papers involve people. Jetté et al. tested it in rats (2005). Alba et al. tested it in GHRH-deficient mice (2006). Teichman et al., Ionescu and Frohman, and Sackmann-Sala et al. tested it in healthy adults (2006, 2006, 2009). One registered phase 2 study, NCT00267527, has no results. A ClinicalTrials.gov search for CJC-1295 on 14 October 2026 returned that single study. The table below lists each one with its model, measured result and limit.

Is research-use CJC-1295 the same as the material in these studies?

No. The studies above tested the sponsor's trial product, in cells, animals or enrolled participants under study conditions (Teichman et al., 2006). Research-use reference material is a laboratory compound. Everything this page reports describes what happened inside those studies, and a certificate of analysis for one lot cannot carry those results across to another sample. Research material is not a medicine, is not a substitute for one, and is not for human or animal use.

The catalogue lists CJC-1295 (No DAC) and ipamorelin reference material as one blend in a single vial, with the split unstated. Most human results above concern the DAC form, so they are background for the No DAC peptide, not direct evidence. The CJC-1295 and ipamorelin research guide covers the compound families.